New pill targets rare gene in Hard-to-Treat cancers

NCT ID NCT02122913

Completed Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Feb 05, 2026 · Last updated May 15, 2026 · Updated 19 times

Summary

This study tested a new drug called larotrectinib in 75 adults with advanced solid tumors that have a specific gene change (NTRK fusion). The main goal was to check the drug's safety and find the right dose. Participants had cancers that stopped responding to other treatments or had no other options.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING NTRK FUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Hospital of the University of Pennsylvania - Radiology

Philadelphia, Pennsylvania, 19104, United States
Mass General Cancer Center

Boston, Massachusetts, 02114, United States
OHSU Hospital - Neurology

Portland, Oregon, 97239, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
The University of Texas MD Anderson Cancer Center - Texas Medical Center

Houston, Texas, 77030, United States
UCHealth Cancer Center - Anschutz Medical Campus - University of Colorado Cancer Center

Aurora, Colorado, 80045, United States
UH Seidman Cancer Center

Cleveland, Ohio, 44106, United States
UPMC Mercy - Oncology

Pittsburgh, Pennsylvania, 15219, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS HARBORING NTRK FUSION